What is HC Wainwright’s Estimate for NeuroPace Q2 Earnings?

NeuroPace, Inc. (NASDAQ:NPCE) – Equities research analysts at HC Wainwright reduced their Q2 2026 EPS estimates for shares of NeuroPace in a research note issued to investors on Friday, May 15th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.21) per share for the quarter, down from their previous estimate of ($0.20). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for NeuroPace’s Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.12) EPS and FY2027 earnings at $0.10 EPS.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06. NeuroPace had a negative net margin of 21.67% and a negative return on equity of 108.20%. The company had revenue of $22.00 million for the quarter, compared to the consensus estimate of $21.65 million.

NPCE has been the topic of a number of other reports. Wells Fargo & Company upgraded shares of NeuroPace to a “strong-buy” rating in a research report on Wednesday, March 18th. Weiss Ratings restated a “sell (d-)” rating on shares of NeuroPace in a research report on Friday, March 27th. Cantor Fitzgerald upgraded shares of NeuroPace to a “strong-buy” rating in a research report on Wednesday, March 4th. Finally, Wall Street Zen lowered shares of NeuroPace from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $18.83.

NeuroPace Stock Performance

NASDAQ:NPCE opened at $15.99 on Tuesday. The firm’s 50-day moving average is $15.16 and its 200-day moving average is $15.14. NeuroPace has a 52-week low of $7.56 and a 52-week high of $19.60. The company has a debt-to-equity ratio of 4.08, a quick ratio of 4.35 and a current ratio of 5.38. The company has a market cap of $545.10 million, a price-to-earnings ratio of -24.60 and a beta of 1.92.

Hedge Funds Weigh In On NeuroPace

A number of large investors have recently modified their holdings of the stock. Legal & General Group Plc lifted its position in shares of NeuroPace by 86.0% during the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock worth $30,000 after purchasing an additional 1,239 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of NeuroPace by 2.5% during the third quarter. GSA Capital Partners LLP now owns 54,536 shares of the company’s stock worth $562,000 after buying an additional 1,323 shares during the period. Quarry LP boosted its position in shares of NeuroPace by 94.9% during the third quarter. Quarry LP now owns 3,845 shares of the company’s stock worth $40,000 after buying an additional 1,872 shares during the period. Man Group plc boosted its holdings in NeuroPace by 9.7% during the fourth quarter. Man Group plc now owns 21,626 shares of the company’s stock worth $334,000 after purchasing an additional 1,920 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in NeuroPace by 23.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,836 shares of the company’s stock worth $230,000 after purchasing an additional 2,778 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About NeuroPace

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.